Fig 1: Proof of concept of in vitro arginylation assay for identification of endogenous arginylation events. a, Reaction scheme of RARS1 charging the R-tRNA, followed by incubation with ATE1 and CALR to allow N-terminal installation of the arginyl modification. b, MS1 charge state distribution and measured monoisotopic mass of commercial CALR shown as an average scan across the chromatographic peak, and a focused view of m/z 800-900 to visualize unmodified CALR peaks. c, MS1 charge state distribution and measured monoisotopic mass of commercial CALR after ATE1 installation of arginyl modification, shown as an average scan across the chromatographic peak. The focused view of m/z 800-900 allows visualization of mass shift compared to the unmodified CALR peaks.
Fig 2: Proof of concept of in vitro arginylation assay for identification of endogenous arginylation events. a, Calreticulin arginylation scheme using Halo-tag purified calreticulin and light or heavy arginine. b, MS1 charge state z = 59 shows mass shift of CALR to R0-CALR, and XIC of three charge states shows arginylation efficiency of 60.3%. c, MS1 charge state z = 59 shows mass shift of CALR to R10-CALR, and XIC of three charge states shows arginylation efficiency of 73.8%. d, MS2 spectra confirms N-terminal installation of R0 modification with signature c1 ion (m/z 174.13). e, MS2 spectra confirms N-terminal installation of R10 modification with signature c1 ion (m/z 184.14), and a shift of 10 Da of all c-ions from the R0 spectra shown above.
Fig 3: Affinity pulldown and purification of CALR and R-CALR proteins. a, schematic for design and purification strategies of CALR proteins. The signal peptide was co-translationally cleaved, and the resulting mature proteins were bound to HaloTag beads. Upon removal of interacting proteins by 8 M urea, proteins were cleaved from beads by TEV protease to yield the desired proteins. b, gel visualization of overexpression and purified CALR proteins. Proteins with and without Halo tag were shown with different molecular weights on gels. Anti-flag and anti-ATE1 antibodies were used for western blotting against the ATE1 protein.
Fig 4: Identification of endogenously arginylated calreticulin in the presence of co-overexpressed ATE1 enzyme. a, MS2 spectra confirming the absence of N-terminal arginylation in the control sample, as indicated by the lack of the c3 ion (m/z 400.23), and confirming the presence of N-terminal arginylation, indicated by the low-level presence of the c1 ion after transient expression of ATE1 enzyme in samples 2-4 and high signal in sample 5. b, The percent signal of R-CALR from the total MS1 calreticulin signal, calculated from XIC of three charge states of each species.
Fig 5: Summary of arginylation sites and ATE1 substrates in human proteins and proteomes.a, experimental workflow for CALR arginylation. b, numbers of identified MS1 pairs, arginylation sites, unique peptides and unique proteins in human cells and patient tissues. c, overview of arginylation sites in human cells and patient tissues. d, ratio plot of all MS1 pairs detected in all sample fractions. e, sequence logo calculated from unmodified forms of all unique arginylated peptides. Frequency plots are generated by WebLogo. f, arginylation type comparison of all unique sites. g, arginylation site comparison between sample types. h, biofunction analysis of ATE1 protein substrates using PANTHER. iPSC, induced pluripotent stem cell. CF, cardiac fibroblasts. CM, cardiomyocytes. R, arginylation. RO3, Cys tri-oxidation and arginylation. RO2, Cys di-oxidation and arginylation. R_deami, N/Q arginylation after deamidation. PD, Parkinson’s disease. PDD, PD with dementia. AD, Alzheimer’s disease.
Supplier Page from Abcam for Recombinant Human Calreticulin protein (His tag)